PUBLICATIONS

Review

OUR PUBLICATIONS

EXTERNAL SESSION CHAIR/ORAL PRESENTATION

1.Timothy Schulz-Utermoehl (2012) Chair of the Virtual/Outsourcing DMPK plenary session. DMDG Annual Conference, Loughborough, UK.

2.Timothy Schulz-Utermoehl (2012) Chair of Roundtable Discussion Session III. 3rd Annual Clinically Relevant Drug Transporters Conference, London, UK

3.Timothy Schulz-Utermoehl (2010) Oral Presenter, Evaluating metabolism-based drug toxicity in development. 5th Annual ADMET Conference, London, UK

4.Timothy Schulz-Utermoehl (2008) Chair of Poster Blitz Oral Communications session. DMDG Annual Conference, Nottingham, UK.

5.Timothy Schulz-Utermoehl (2005) Chair of Free Communications session. DMDG Annual Conference, Cambridge, UK.

6.Timothy Schulz-Utermoehl (2003) Oral Presenter. DMDG One Day Meeting on Reactive Metabolites, Wellingborough, UK.

FULL PAPERS

1. Nicholas J Coltman, Brandon A Coke, Kyriaki Chatzi, Emma L Shepherd, Patricia F Lalor, Timothy Schulz-Utermoehl, Nikolas John Hodges. (2021) Application of HepG2/C3A liver spheroids as a model system for genotoxicity studies. Arch Toxicol (in press).

2. Xingjian Li, Daniel T. Payne, Badarinath Ampolu, Nicholas Bland, Jane T. Brown, Mark J. Dutton, Catherine A. Fitton, Abigail Gulliver, Lee Hale, Daniel Hamza, Geraint Jones, Rebecca Lane, Andrew G. Leach, Louise Male, Elena G. Merisor, Michael J. Morton, Alex S. Quy, Ruth Roberts, Rosanna Scarll, Timothy Schulz-Utermoehl, Tatjana Stankovic, Brett Stevenson, John S. Fossey, and Angelo Agathanggelou (2019) Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. MedChemComm 10(8), 1379-1390.

3. Kathryn Pickup, Scott Martin, Elizabeth A. Partridge, Huw B. Jones, Jonathan Wills, Tim Schulz-Utermoehl, Alan McCarthy, Alison Rodrigues, Chris Page, Kerry Ratcliffe, Sunil Sarda, and Ian D. Wilson (2017) Acute liver effects, disposition and metabolic fate of [14C]-fenclozic acid following oral administration to normal and bile-cannulated male C57BL/6J mice. Arch Toxicol 91(7), 2643-2653.

4.Uchea C, Sarda S, Schulz-Utermoehl T, Owen SF, Chipman JK (2013) in vitro models of xenobiotic metabolism in trout for use in environmental bioaccumulation studies. Xenobiotica 43(5), 421-431.

5.Rodrigues, AVM, Rollison H, Martin S, Sarda S, Schulz-Utermoehl T, Stahl S, Gustafsson F, Eakins J, Kenna JG, Wilson ID (2013) In vitro exploration of potential mechanism of toxicity of the human hepatotoxic drug fenclozic acid. Arch Toxicol, 87, 1569-1579.

6.Samuelsson K, Pickup K, Sarda S, Swales J, Morikawa Y, Schulz Utermoehl T, Hutchison M and Wilson I D (2012) Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. Xenobiotica 42(11), 1128-1137.

7.Foster J R, Jacobson M, Kenna G, Schulz-Utermoehl T, Morikawa Y, Salmu J, Wilson I D (2012) Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol Pathol 40(8), 1106-1116.

8.Schulz-Utermoehl T, Foster J R, Gross G, Jacobson M, Kenna G, Morikawa Y, Salmu J, Sarda S, Wilson I D (2012) Evaluation of the pharmacokinetics, biotransformation and hepatic effects of troglitazone in mice with humanised livers. Xenobiotica 42(6), 503-517.

9.Sarda S, Page C, Pickup K J, Schulz-Utermoehl T, Wilson I D (2012) Diclofenac metabolism in the mouse: Novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica 42(2), 179-194.

10.Pickup K J, Gavin A, Jones H, Karlsson E, Page C, Ratcliffe K, Sarda S, Schulz-Utermoehl T, Wilson I D (2012) The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: Application to the metabolism of diclofenac. Xenobiotica, 42(2), 195-205.

11.Schulz-Utermoehl T, Spear M, Pollard CRJ, Pattison, C, Rollison H, Sarda S, Ward M, Bushby N, Jordan A, Harrison M (2010). In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: Interspecies comparison and human enzymology. Drug Metab Dispos, 38 (10), 1688-1697.

12.Lenz E, Spear M, Drake C, Ward M, Schulz-Utermoehl T, Harrison M (2010) Characterisation and identification of the unique human N+-glucuronide metabolite of cediranib. J of Pharmaceutical and Biomedical Analysis, 53(3), 526-536.

13.Meneses-Lorente G, Sakatis M, Schulz-Utermoehl T, Watt AP (2006) A quantitative high throughput trapping assay as a measurement of potential for bioactivation. Anal Biochem 351(2), 266-272.

14.Day SH, Mao A, Schulz-Utermoehl T, Miller R, Beconi MG (2005) A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods 52(2), 278-285.

15.Schulz TG, Thiel R, Neubert D, Brassil PJ, Schulz-Utermoehl T, Boobis AR, Edwards RJ (2001) Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. Biochem Biophys Acta 1546(1), 143-155.

16.Schulz-Utermoehl T, Mountfield R J, Madsen K, Jorgensen P N, Bywater R, Hansen K T. (2000) Structure-function analysis of human CYP3A4 using a specific pro-inhibitory antipeptide antibody. Drug Metab Dispos 28, 718-725.

17.Schulz-Utermoehl T, Boobis A R, Edwards R J. (2000) The affinity and potency of pro-inhibitory antipeptide antibodies toward CYP2D6 is enhance using cyclic peptides as immunogens. Drug Metab. Dispos 28, 544-551.

18.Schulz-Utermoehl T, Mountfield R J, Madsen K, Jorgensen P N, Hansen K T. (2000)  Selective and potent inhibition of human CYP2C19 activity by a conformationally targeted antipeptide antibody. Drug Metab Dispos 28, 715-717.

19.Schulz-Utermoehl T, Bennett A J, Ellis S W, Tucker G T Boobis A R, Edwards R J. (1999) Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9, 357-366.

20.Riedl AG, Brown C T, Rose S, Schulz-Utermoehl T, Edwards R J, Boobis A R, Jenner P. (1999) Localisation and manipulation of CYP2D enzymes in naïve rat basal ganglia. Brain Research 822, 175-191.

ABSTRACTS  & POSTERS

1.C Uchea, T Schulz-Utermoehl, S F Owen, J K Chipman (2011) In vitro models of xenobiotics metabolism in trout: potential use in prediction of bioaccumulation and “read-across” studies. Poster, presented 21st SETAC Europe Annual Meeting, Milan, UK.

2.Alan Barnes, Neil Loftus, Ian Wilson, Timothy Schulz-Utermoehl, Filippos Michopoulos, Yoshio Morikawa (2011) Troglitazone metabolism in a chimeric mouse model with humanised livers determined by high mass accuracy MSn analysis. Poster, presented at BMSS, Cardiff, UK.

3.C Uchea, H S Jones, G H Panter, T H Hutchinson, T Schulz-Utermoehl, S F Owen, J K Chipman (2011) In vitro models of xenobiotics metabolism in trout: potential use in prediction of bioaccumulation and interspecies differences. Presentation, presented at PRIMO (Pollutant Responses in Marine Organisms), Long Beach, USA.

4.Eleanor Q. Blatherwick; Kathryn J. Pickup; Sunil Sarda; Timothy Schulz-Utermoehl; Ian D. Wilson; Daniel J. Weston; James H. Scrivens (2011) Imaging mass spectrometry based approaches to the localisation of drugs and drug metabolites in animal tissue. Poster, presented at ASMS, Colorado, USA.

5.Alan Barnes, Neil Loftus, Ian Wilson, Timothy Schulz-Utermoehl, Filippos Michopoulos, Yoshio Morikawa (2011) Troglitazone metabolism in a chimeric mouse model with humanised livers determined by high mass accuracy MSn analysis. Poster, presented at ASMS, Colorado, USA.

6.John R. Foster, Gerhard Gross, Clare Hammond, Matt Jacobsen, Gerry Kenna, Yoshio Morikawa, Filippos Michopoulos, Raimund Peter, Juuso Salmu, Sunil Sarda, Timothy Schulz Utermoehl and Ian D. Wilson (2010) Troglitazone in a Chimeric Mouse with Humanised Liver: Comparison of the Pharmacokinetics, Metabolism and Biological Effects to a Normal Mouse. Poster, presented at International ISSX Meeting, Istanbul, Turkey.

7.Michopoulos Filippos, Spagou Konstantina, Schulz-Utermoehl Timothy, Wilson Ian D (2010) Metabonomic evaluation of the PXB chimeric mice model to study the effect of troglitazone on the liver. Poster, presented at the AstraZeneca DMPK External Science Collaborations Day, Alderley Edge, UK.

8.Pollard, C R J; Duckett, C J; Schulz-Utermoehl, T (2010) [14C]-AZD5438 Hepatotoxicity: An Investigation Using In Vitro Covalent Binding and Metabolite Trapping Techniques. Poster, presented at the AstraZeneca DMPK External Science Collaborations Day, Alderley Edge, UK.

9.John R. Foster, Gerhard Gross, Clare Hammond, Matt Jacobsen, Gerry Kenna, Yoshio Morikawa, Filippos Michopoulos, Raimund Peter, Juuso Salmu, Sunil Sarda, Timothy Schulz Utermoehl, Michelle Ward and Ian D. Wilson (2010) Troglitazone in a Chimeric Mouse with Humanised Liver: Comparison of the Pharmacokinetics, Metabolism and Biological Effects to a Normal Mouse. Poster, DMDG Annual Meeting, Canterbury, UK.

10.M. Spear, C.R.J. Pollard, C. Pattison, S. Sarda, H. Rollison, M. Ward, M. Harrison & T. Schulz-Utermoehl (2009) Hepatic metabolism of cediranib, a potent VEGF inhibitor: interspecies comparison and human enzymology. Poster, presented at 16th American ISSX Meeting, Baltimore, USA.

11.E. Lenz, C. Drake, M. Spear, S. Kelly, M. Harrison & T. Schulz-Utermoehl (2009) Characterisation and identification of the N-glucuronide metabolite of cediranib. Poster, presented at 16th American ISSX Meeting, Baltimore, USA.

12.E. Lenz, C. Drake, M. Spear, S. Kelly, M. Harrison & T. Schulz-Utermoehl (2009) Characterisation and identification of cediranib N+-glucuronide metabolite. Poster, presented at SMASH NMR Meeting, Baltimore, Chamonix, France.

13.C.R.J Pollard, M. Greer, T. Schulz-Utermoehl & CJ. Duckett (2009) Elucidating the mechanism of AZD5438 reactive metabolism. Poster, to be presented at the Gordon Research Conference, Holderness, USA.

14.C. Pattison, H. Wortelboer, J. Muir, M. Mulderij, M. Usta, M. Harrison & T. Schulz-Utermoehl (2009) The involvement of efflux transporters in cediranib disposition and drug interactions. Poster, 11th European ISSX Meeting, Lisbon, Portugal.

15.S. Kelly, T. Schulz-Utermoehl & H. Wortelboer (2009) AZD0530 is a substrate of the organic cation transporter, OCT2. Poster, DMDG Spring Meeting, Stevenage, UK.

16.H. Rollison, C. Pattison, M. Spear, T. Schulz-Utermoehl, A McCormick & M. Ward (2008) Investigating the relative importance of CYP and UGT enzymes in the formation of reactive metabolites of carboxylic acid drugs. Poster, DMDG Annual Meeting, Nottingham, UK.

17.C.R.J. Pollard, T. Schulz-Utermoehl, S. Sarda, J.J. Young & C.J. Duckett (2008) The Metabolism of the CDK Inhibitor AZD5438 in Human Systems: Potential Formation of Reactive Intermediates. Poster, 10th European ISSX Meeting, Vienna, Austria.

18.H.M. Wortelboer, T. Schulz-Utermoehl, S. Kelly, G. Nichols, M. Verwei, N.H.P. Cnubben, & F.C.S. Salmon (2008) Issues With Interpreting In Vitro Efflux Transporter Data Using The Bidirectional Transport Assay. Poster, 10th European ISSX Meeting, Vienna, Austria.

19.C.R.J. Pollard, T. Schulz-Utermoehl, S. Sarda, J.J. Young & C.J. Duckett (2007) The in vitro and in vivo metabolism of AZD5438 in human – potential formation of a reactive intermediate. Poster, DMDG Annual Meeting, Cambridge, UK.

20.S.F. Owen, G.H. Panter, C.R.J. Pollard, T. Schulz-Utermoehl, D.B. Huggett, L.A. Constantine & M.J. Hetheridge (2008) Comparative metabolism of pharmaceuticals in trout and rats. Poster and Oral Presentation, SETAC Europe 18th Annual Meeting, Warsaw, Poland.

21.G.H. Panter, S.F. Owen, C.R.J. Pollard, K.H. Hutchinson, I.R. Crooks, T. Schulz-Utermoehl & M.J. Hetheridge (2007) Strategy to examine pharmaceutical metabolism in fish. Poster, ERAPharm, York, UK.

22.H.M. Wortelboer, C. Pattison, S. Pavan, M. Mulderij, F.L. Schrander, J. Young & T. Schulz-Utermoehl (2007) Determination of the involvement of human transport proteins MDR1 and BCRP in the transport of AZD1152 hydroxy QPA. Poster, DMDG Annual Meeting, Cambridge, UK.

23.T. Schulz-Utermoehl & S. Kelly (2007) Issues with interpreting in vitro efflux transporter data. Poster, AstraZeneca Drug Transporter One Day Meeting. Loughborough, UK.

24.M. Spear, A. McCormick, S. Sarda, T. Schulz-Utermoehl & D. Roberts (2006) Bioactivation of the Chk Kinase Inhibitor, AZD7762, by Human and Rat Liver Microsomes. Poster, AstraZeneca DMPK One Day Meeting, Loughborough, UK.